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interest in our recent study (1, 2). We agree that human
papillomavirus (HPV) status does predict for disease
outcome, even in the reirradiation setting, as demonstrated by
Davis et al (3). These are challenging analyses to do given the
differences in recurrence patterns in patients who are HPV
positive, in terms of location, time to recurrence, and the
changing epidemiology of HPV positivity. In our study, p16
status was used as a surrogate for HPV positivity. p16 protein
status was available for 27 of the 173 head and neck squa-
mous cell cancer patients and did not significantly influence
survival or tumor control, as demonstrated in Supplementary
Figure 1 and Supplementary Table S2 in our article (1).
Patients with an initial diagnosis of nasopharyngeal
carcinoma overall constituted a minority of patients in the
dataset. As Dr. Mansha alluded, tumor outcomes among
nasopharyngeal carcinoma patients were notably better
than in those with tumors involving other head and neck
subsites, with 2-year locoregional control and progression-
free survival rates of 86% and 73%, respectively. This is
consistent with prior reports (4-7). Of the 16 patients with
initial nasopharyngeal presentation, 3 presented with
intracranial extension (T4) disease.
Last, in regard to relevant organ-at-risk doses, we believe
detailed volumetric analyses are required for this information
to be useful. These investigations are the subject of future
research. Previous publications from other institutions have
addressed maximum point doses, although the clinical
applicability of this information remains less clear (8, 9).
Although we have attempted to present a thorough and
coherent analysis of our data using intensity modulated radi-
ation therapy for head and neck reirradiation, there are clearly
many questions that remain to be explored in future studies.
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“Freezing” the Tumor in a Known Position
During Radiation TherapyIn Regard to Boda-Heggemann
et alTo the Editor: It was always hoped that if patients held their
breath, tumors would stay still. The introduction of multiple
short (roughly 20-second) breath-holds in air, to reduce the
movement of target organs, is improving radiation therapy
delivery for breast cancer (1) and ought to improve the de-
livery for other thoracic and abdominal tumors. It is impor-
tant, however, to be aware that tumors do not stay completely
still during breath-holding (2-4). First, there is settlement of
Comments International Journal of Radiation Oncology  Biology  Physics710the chest, diaphragm, and abdominal organswhen the breath-
hold is first established (3, 5, 6). Second, there is shrinkage of
the chest volume throughout breath-holding because oxygen
continues to be extracted from alveolar gas and is not
replaced by an equal volume of carbon dioxide (7). These
physiological changes are in addition to the issues of repro-
ducibility of organ position between each breath-hold.
Colleagues should also be aware that patients with
cancer can already breath-hold for >10 times longer than in
these multiple short breath-holds using air (1). Parkes et al
(3) have just achieved single prolonged breath-holds for
>5 minutes using a non-invasive mechanical ventilation
technique with 60% oxygen. Here, the initial settlement
movement over the first 10 to 15 seconds of the breath-hold
was typically 3 mm, and in 15 patients the chest deflated by
about 2 mm/min in the inferior-superior direction (the di-
rection of largest motion in this study). Peguret et al (2)
have achieved single “apnea-like breath-holds” for
>11 minutes using a high-frequency percussive ventilation
technique with 100% oxygen. Movements during their
ventilation technique were measured with computed to-
mography and evaluated in detail in 2 patients, showing
movement from the start to the end of the ventilation that
was typically 2 to 4 mm and occasionally larger.
Whereas such prolonged breath-holding techniques have
further clinical potential to optimize both imaging and
delivery of x-ray and particle beam therapy in a single
breath-hold, they also emphasize the urgent need for more
research on the position changes of both tumors and healthy
tissue throughout breath-holding.
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